Evidence map›Paper›PMID 40501603›Full record

ArticlebioRxiv : the preprint server for biology2025

The mGluR5 Agonist, CHPG, Enhances Numbers of Differentiated Human Oligodendrocytes.

Yangyang Huang, Celine Geywitz, Anjalika Bandaru, Ian A Glass, Birth Defects Research Laboratory, Lucas Schirmer, Hiroko Nobuta, Cheryl Dreyfus

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Yangyang HuangDepartment of Neuroscience and Cell Biology, Rutgers University, Piscataway, NJ 08854, USA.
Celine GeywitzInterdisciplinary Center for Neurosciences, Heidelberg University, Mannheim, Germany.
Anjalika BandaruSchool of Environmental and Biological Sciences, Rutgers University, Piscataway, NJ 08854, USA.
Ian A GlassUniversity of Washington, Seattle, WA 98105, USA.
Birth Defects Research Laboratory
Lucas SchirmerInterdisciplinary Center for Neurosciences, Heidelberg University, Mannheim, Germany.ORCID 0000-0001-7142-4116
Hiroko NobutaDepartment of Neuroscience and Cell Biology, Rutgers University, Piscataway, NJ 08854, USA.
Cheryl DreyfusDepartment of Neuroscience and Cell Biology, Rutgers University, Piscataway, NJ 08854, USA.

Funding

LABORATORY OF DEVELOPMENTAL BIOLOGYR24HD000836 · NICHD · UNIVERSITY OF WASHINGTON · PI Ian Amos Glass · 1995 to 2026
$16.9M
NICHD NIH HHS R24 HD000836
6 · The paper itself

Abstract

Previous studies on adult mice indicate that the mGluR5 agonist 2-chloro-5-hydroxyphenyl glycine (CHPG), reduces cuprizone-elicited losses in myelin. This effect is partly mediated by CHPG binding to mGluR5 receptors on reactive astrocytes, triggering the release of brain derived neurotrophic factor (BDNF), which results in an increase in myelin, and alleviates behavioral deficits. However, it remains unclear whether CHPG has similar beneficial effects on human cells. To address this issue, we examined effects of CHPG on human cells using both human induced pluripotent stem cell (hiPSC)-derived oligodendrocytes and primary human fetal brain cells. Treatment of hiPSCs (30μM, 5 days) or primary cells (30 μM, 3 days) with CHPG increases the percent of MBP

Indexed as

demyelinationhuman primary cellsinduced pluripotent stem cellsmultiple sclerosisOligodendrocytepostmortem tissuesremyelination

Identifiers

PMID40501603
PMCPMC12154948

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.